Brexpiprazole is under clinical development by Otsuka Pharmaceutical and currently in Pre-Registration for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Pre-Registration drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Pre-Registration. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Brexpiprazole LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brexpiprazole overview

Brexpiprazole (Rexulti, Rxulti) is a quinolinone derivative, acts as anti-psychotic agent. It is formulated as tablets, and film coated tablets for oral route of administration. Rexulti is indicated for treatment of schizophrenia, as a maintenance treatment of schizophrenia in adults and as an adjunctive treatment of major depressive disorder (MDD) and depression. Rexulti is indicated for the treatment of adult and pediatric patients of age with 13 years and older.

It is under development for the treatment of post-traumatic stress disorder (PTSD), agitation associated with dementia of the Alzheimer's type (AADAD) and schizophrenia. It was also under development for the treatment of attention deficit hyperactivity disorder, borderline personality disorder, irritability associated with pervasive developmental disorder, and bipolar disorder.

Otsuka Pharmaceutical overview

Otsuka Pharmaceutical (OPC), a subsidiary of Otsuka Holdings Co Ltd, is a manufacturer and supplier of pharmaceuticals, food products, clinical testing, and medical equipment. The company develops formulations for the diagnosis and treatment of central nervous system, oncology, cardiovascular and renal, gastrointestinal, ophthalmology disorders and infectious diseases through its pharmaceutical business. Its nutraceutical segment offers rehydration, nutrition, vitamin supplements and cosmetics. OPC is investigating drugs for psychiatry and neurology; oncology; cardiovascular and other therapeutic indications in collaboration with academia and venture companies. The company operates branch offices, research facilities and factories in Japan. OPC is headquartered in Chiyoda-ku, Tokyo, Japan.

For a complete picture of Brexpiprazole’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.